BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9607022)

  • 1. Safety and immunogenicity of REMUNE in HIV-infected Thai subjects.
    Limsuwan A; Churdboonchart V; Moss RB; Sirawaraporn W; Sutthent R; Smutharaks B; Glidden D; Trauger R; Theofan G; Carlo D
    Vaccine; 1998; 16(2-3):142-9. PubMed ID: 9607022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of HIV-1-infected Thai patients immunized with Remune monotherapy.
    Sukeepaisarncharoen W; Churdboonchart V; Kulpradist S; Isarangkura Na Ayudthya B; Rugpao S; Chandeying V; Sirawaraporn W; Carlo D; Moss RB
    HIV Clin Trials; 2001; 2(5):391-8. PubMed ID: 11673813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected thai subjects with CD4-cell counts of >300.
    Churdboonchart V; Sakondhavat C; Kulpradist S; Na Ayudthya BI; Chandeying V; Rugpao S; Boonshuyar C; Sukeepaisarncharoen W; Sirawaraporn W; Carlo DJ; Moss R
    Clin Diagn Lab Immunol; 2000 Sep; 7(5):728-33. PubMed ID: 10973445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in Thailand.
    Churdboonchart V; Moss RB; Sirawaraporn W; Smutharaks B; Sutthent R; Jensen FC; Vacharak P; Grimes J; Theofan G; Carlo DJ
    AIDS; 1998 Aug; 12(12):1521-7. PubMed ID: 9727574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed progression to AIDS in volunteers treated with long-term HIV-1 Immunogen (REMUNE) therapy in Thailand.
    Chantratita W; Sukeepaisarncharoen W; Chandeying V; Kulpradist S; Israngkura Na Ayudhtaya B; Rugpao S; Sirawaraporn W; Boonshuyar C; Churdboonchart V
    HIV Med; 2004 Sep; 5(5):317-25. PubMed ID: 15369506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjects.
    Moss RB; Giermakowska W; Lanza P; Turner JL; Wallace MR; Jensen FC; Theofan G; Richieri SP; Carlo DJ
    Viral Immunol; 1997; 10(4):221-8. PubMed ID: 9473153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor alpha and human immunodeficiency virus-specific functional immune responses after immunization with Gp120-depleted, inactivated HIV-1 in incomplete Freund's adjuvant (REMUNE) in HIV-1-seropositive subjects.
    Moss RB; Li L; Giermakowska WK; Lanza P; Turner JL; Wallace MR; Jensen FC; Richieri SP; Daigle AE; Theofan G; Carlo DJ
    J Hum Virol; 1998; 1(2):77-81. PubMed ID: 10195235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro p24 antigen-stimulated lymphocyte proliferation and beta-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune).
    Moss RB; Wallace MR; Lanza P; Giermakowska W; Jensen FC; Theofan G; Chamberlin C; Richieri SP; Carlo DJ
    Clin Diagn Lab Immunol; 1998 May; 5(3):308-12. PubMed ID: 9605982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential role of the HIV-1 immunogen (Remune) as a therapeutic vaccine in the treatment of HIV infection.
    Fernández-Cruz E; Navarro J; Rodríguez-Sainz C; Gil J; Moreno S; González-Lahoz J; Carbone J
    Expert Rev Vaccines; 2003 Dec; 2(6):739-52. PubMed ID: 14711358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rebuilding immunity with Remune.
    Whitfield L
    Posit Aware; 1998; 9(3):39-40. PubMed ID: 11365486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs.
    Turner JL; Kostman JR; Aquino A; Wright D; Szabo S; Bidwell R; Goodgame J; Daigle A; Kelley E; Jensen F; Duffy C; Carlo D; Moss RB
    HIV Med; 2001 Apr; 2(2):68-77. PubMed ID: 11737381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of HIV-specific lymphocyte proliferative immune responses induced by therapeutic vaccination.
    Moss RB; Wallace MR; Steigbigel RT; Morrison SA; Giermakowska WK; Nardo CJ; Diveley JP; Carlo DJ
    Clin Exp Immunol; 2002 May; 128(2):359-64. PubMed ID: 11985528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A primer on HIV type 1-specific immune function and REMUNE.
    Moss RB; Giermakowska WK; Savary JR; Theofan G; Daigle AE; Richieri SP; Jensen FC; Carlo DJ
    AIDS Res Hum Retroviruses; 1998 Jun; 14 Suppl 2():S167-75. PubMed ID: 9672235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A boost for the immune system.
    TreatmentUpdate; 1998 Nov; 10(9):3-4. PubMed ID: 11365925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic vaccine trails in Thailand.
    Churdboonchart V
    J HIV Ther; 2004 Sep; 9(3):57-9. PubMed ID: 15534562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults.
    Pitisuttithum P; Nitayaphan S; Thongcharoen P; Khamboonruang C; Kim J; de Souza M; Chuenchitra T; Garner RP; Thapinta D; Polonis V; Ratto-Kim S; Chanbancherd P; Chiu J; Birx DL; Duliege AM; McNeil JG; Brown AE;
    J Infect Dis; 2003 Jul; 188(2):219-27. PubMed ID: 12854076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials of HIV treatment begin in Thailand.
    AIDS Wkly Plus; 1996 Apr 8-15; ():14. PubMed ID: 12320053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gpl60 vaccine among adults with advanced HIV infection. Massachusetts gp160 Working Group.
    DeMaria A; Kunches L; Mayer K; Cohen C; Epstein P; Werner B; Day J; DeCristofaro J; Landers S; Tang Y; Coady W
    J Hum Virol; 2000; 3(4):182-92. PubMed ID: 10990166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective analyses of HIV-1-specific proliferative responses, recall antigen proliferative responses, and clinical outcomes in an HIV-1-seropositive cohort.
    Ratto-Kim S; Garner RP; Kim JH; Jagodzinski LL; Michael NL; Paris R; Redfield RR; Birx DL
    J Infect Dis; 2004 Jun; 189(11):1988-95. PubMed ID: 15143464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remune. Immune Response.
    Lai D; Jones T
    Curr Opin Investig Drugs; 2002 Mar; 3(3):391-8. PubMed ID: 12054085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.